evaluated
severity
motor disability
dyskinesias
levodopa-responsive
patients
Parkinson's disease
acute
apomorphine
administration
fluoxetine
days
fluoxetine
treatment
improvement
apomorphine-induced dyskinesias
modification
parkinsonian motor disability
dyskinesias
reduced
lower limbs
onset
disappearance
dystonic dyskinesias
end-of-dose dyskinesias
upper limbs
choreic mid-dose dyskinesias
brain
serotoninergic transmission
fluoxetine
levodopa-
dopamine
agonist-induced dyskinesias
aggravating
parkinsonian motor disability
